Senti Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary

Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotech company focused on Gene Circuit platform cell and gene therapies, has granted stock options to eight new employees. The Board approved options to purchase 102,500 shares at an exercise price of $3.03 per share on June 3, 2025. These inducement equity awards were granted under the company's Amended and Restated 2022 Inducement Equity Plan, which was initially adopted on August 5, 2022. The grants were made in accordance with NASDAQ Listing Rule 5635(c)(4) as material inducement for the new employees joining the company.

SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on June 3, 2025 Senti Bio’s Board of Directors granted to eight new employees stock options to purchase an aggregate of 102,500 shares of the Company’s common stock with a per share exercise price of $3.03. These awards were made under the Company’s Amended and Restated 2022 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was initially adopted by the Company’s board of directors on August 5, 2022.

About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.

Availability of Other Information About Senti Bio
For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on X (formerly Twitter) (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
snti@jtcir.com  

FAQ

What stock options did Senti Biosciences (SNTI) grant to new employees in June 2025?

Senti Biosciences granted stock options to eight new employees to purchase 102,500 shares at an exercise price of $3.03 per share on June 3, 2025.

What is the purpose of SNTI's 2022 Inducement Equity Plan?

The Inducement Equity Plan is designed to provide stock options as material inducement for new employees joining Senti Biosciences, in accordance with NASDAQ Listing Rule 5635(c)(4).

When was Senti Biosciences' Inducement Equity Plan initially adopted?

Senti Biosciences' board of directors initially adopted the Inducement Equity Plan on August 5, 2022.

What is Senti Biosciences' main business focus?

Senti Biosciences is a clinical-stage biotechnology company that develops next-generation cell and gene therapies using its proprietary Gene Circuit platform.